US 12,351,582 B2
Aurora kinase inhibitors and uses thereof
Yuli Xie, Shanghai (CN); and Houxing Fan, Shanghai (CN)
Assigned to WIGEN BIOMEDICINE TECHNOLOGY (SHANGHAI) CO., LTD., Shanghai (CN)
Filed by WIGEN BIOMEDICINE TECHNOLOGY (SHANGHAI) CO., LTD., Shanghai (CN)
Filed on Mar. 14, 2021, as Appl. No. 17/200,854.
Application 17/200,854 is a continuation of application No. PCT/CN2020/098775, filed on Jun. 29, 2020.
Claims priority of application No. 201910643061.2 (CN), filed on Jul. 16, 2019.
Prior Publication US 2021/0198261 A1, Jul. 1, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 471/14 (2006.01); C07D 401/14 (2006.01)
CPC C07D 471/14 (2013.01) [C07D 401/14 (2013.01); C07B 2200/05 (2013.01)] 6 Claims
 
1. A compound of formula (1), an optical isomer, a crystalline form, or a pharmaceutically acceptable salt thereof:

OG Complex Work Unit Chemistry
in formula (1):
R1 is aryl, heteroaryl,

OG Complex Work Unit Chemistry
 or

OG Complex Work Unit Chemistry
 wherein the aryl and the heteroaryl is optionally substituted by 1-3 groups selecting from the group consisting of halogen, C1-C3 alkyl, C1-C3 alkoxyl, halogen substituted C1-C3 alkyl and halogen substituted C1-C3 alkoxyl;
R2 is H or methyl;
R3 is H or F;
W is

OG Complex Work Unit Chemistry
 wherein Ra is H, C1-C3 alkyl or C3-C6 cycloalkyl; and
L is CH2, CO, CD2, CH(Me), C(Me)2,

OG Complex Work Unit Chemistry
 or

OG Complex Work Unit Chemistry